Ex-justice minister's daughter attends forgery trial in college admissions scandal
US defense policy bill calls for maintaining 28,500 US troops in Korea
S. Korea determined to become tourism powerhouse
S. Korea logs current account surplus for 6th month in October
4 contentious bills scrapped in revote after Yoon's veto
Footballer Hwang's sister-in-law indicted for disclosing his private videos
Turkish woman gets jail term for killing abusive boyfriend
[Travel Bits] Festivals, sights across Korea
Ex-Democratic Party chair denies bribery, illegal campaign allegations
US trade body finds no patent breaches by Samsung over digital signage: sources
[Newsmaker] Celltrion confirms phase 1 trial safety of COVID-19 antibody drug
Global clinical phase 2, 3 trials to take place in as many as 12 nationsBy Lim Jeong-yeo
Published : Sept. 11, 2020 - 14:36
Once another clinical phase 1 trial targeting light-symptom COVID-19 patients wraps up, Celltrion plans to proceed to global phase 2 and 3 trials in as many as 12 nations targeting 500 patients.
Clinical test designs for these global trials have already been submitted in seven countries, Celltrion said.
Although the company refrained from sharing where these countries are, a Celltrion official said that by testing CT-P59 in diverse territories, the drug may prove its efficacy in fighting various mutations of SARS CoV-2 virus.
The company aims to gather midterm trial results from global trials by end-2020 and finish development of CT-P59 within the first half of 2021, Celltrion said.
CT-P59 is entering mass production this month, according to Celltion, to preemptively meet the demands upon development completion.
“We aspire to deliver the drug as quickly as possible through an emergency usage application by yearend,” said a Celltrion official.
CT-P59 is being developed jointly by Celltrion and Korea Centers for Disease Control and Prevention.
In Korea, Celltrion had two clinical phase 1 trials undergoing; one that has wrapped up Friday had tested the drug on 32 healthy candidates to see the drug’s toxicity and absorption rate in the human body.
In maximum dosages per cohort, CT-P59 triggered no abnormalities in patient reactions, Celltrion announced.
By Lim Jeong-yeo (firstname.lastname@example.org)
S. Korea, US., Japan reaffirm N. Korea's denuclearization obligation
Government asks young couples why they refuse to have children
[Weekender] [K-School] From lobster to rose tteokbokki, Korean school food continues to evolve